SCHEMBL6406892

SCHEMBL6406892

Fc1ccccc1Oc1nccc(-c2ccccc2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
MAPK14 Q16539 3/20 0.48
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47
GAA P10253 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
AURKA O14965 1/20 0.45
HSP90AA1 P07900 1/20 0.45
PRKACA P17612 1/20 0.45
ADORA2A P29274 1/20 0.45
HTT P42858 1/20 0.45
RXRA P19793 1/20 0.43
GRIN1 Q05586 1/20 0.43
GRIN2B Q13224 1/20 0.43
ALOX5AP P20292 5/20 0.42
FEN1 P39748 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL667593 0.83 AURKA (0.57) MAPTL3MBTL1LMNACYP1A2GAA
SCHEMBL5119715 0.78 MEN1 (0.57) MAPTL3MBTL1MAPK14LMNACYP1A2
SCHEMBL10187131 0.78 ALOX5AP (0.56) MAPTMEN1KMT2AALOX5APFEN1
SCHEMBL6620934 0.74 MAPK14 (0.48) MAPTL3MBTL1MAPK14ALOX5AP
SCHEMBL2035174 0.73 MEN1 (0.63) MAPTMAPK14CYP1A2GAACYP2C9
SCHEMBL7974844 0.72 MAPK14 (0.41) L3MBTL1MAPK14ALOX5APFEN1
SCHEMBL6406900 0.72 MAPK1 (0.47) MAPTL3MBTL1LMNAMEN1KMT2A
SCHEMBL31721219 0.71 HSP90AA1 (0.50) MAPTL3MBTL1LMNACYP1A2GAA
SCHEMBL6804830 0.71 MEN1 (0.44) MAPTL3MBTL1MAPK14LMNACYP1A2
SCHEMBL10264563 0.70 ADORA2A (0.50) MAPTL3MBTL1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6867210-B2 Aryl substituted pyrimidines EURO-CELTIQUE S.A. (LU) 2005-03-15 US disclosed
US-20050043305-A1 Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof EURO-CELTIQUE S.A. (LU) 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043305-A1 Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof CACNA1S, CACNA1C, KYNU MAPT 585/4885L3MBTL1 178/4885MAPK14 3805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.